Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 29,997	$ 20,337
General and administrative	11,658	10,927
In-process R&D	0	50,618
Total operating expenses	41,655	81,882
Loss from operations	(41,655)	(81,882)
Other income (expense)	2,430	(299)
Loss before income tax expense	(39,225)	(82,181)
Income tax expense	0	0
Net loss	$ (39,225)	$ (82,181)
Net loss per share - basic and diluted (in dollars per share)	$ (0.37)	$ (1.31)
Basic and diluted weighted average shares outstanding (in shares)	105,186	62,870
Other comprehensive loss:
Net loss	$ (39,225)	$ (82,181)
Unrealized loss on marketable securities	(302)	0
Comprehensive loss	$ (39,527)	$ (82,181)